Utah
Prescription drug spending and prescribing in Utah, from Medicare Part D and Medicaid, with the life-science companies raising money there and state attorney general health-care antitrust cases. Compare every state.
In 2024, Medicare Part D plans paid $1.6B for prescriptions written in Utah, the 37th most of 52 states and territories, and 5.1% of its claims were opioids against 3.5% nationally.
- Medicare Part D, 2024: $1.6B
- Medicaid drugs, 2025: $517M
- Opioid share of claims: 5.1%
- Life-science raises, 2 years: $171M
How It Prescribes
Medicare Part D, 2024, by the prescriber's state| Share of Part D claims | Utah | United States | Difference |
|---|---|---|---|
| Opioids | 5.1% | 3.5% | +45% |
| Antibiotics | 4.7% | 4.4% | +7% |
| Antipsychotics | 1.9% | 1.7% | +8% |
Most Distinctive Drugs
Prescribed most out of line with the rest of the country: the drug's share of Utah's claims against its share nationally| Drug | Against national rate | Claims |
|---|---|---|
| Liothyronine Sodium | 4.0× | 18,323 |
| Progesterone, Micronized | 3.5× | 14,220 |
| Buprenorphine Hcl | 3.3× | 11,597 |
| Carisoprodol | 3.2× | 6,816 |
| Insulin Glargine/Lixisenatide | 2.7× | 4,556 |
| Testosterone Cypionate | 2.6× | 17,535 |
| Modafinil | 2.5× | 5,544 |
| Celecoxib | 2.3× | 79,020 |
| Doxycycline Monohydrate | 2.2× | 26,446 |
| 0.9 % Sodium Chloride | 2.2× | 4,619 |
Biggest Medicaid Drugs
What Utah's Medicaid program paid pharmacies, before rebates; see every drugLife-Science Fundraising
30 Form D raises by companies based in Utah in the last two years; the 10 largest. See all raises- Route 92 Medical, Inc.$50M · Other health care · Apr 20, 2026
- Second Heart Assist, Inc.$18M · Biotech · Feb 7, 2025
- Second Heart Assist, Inc.$18M · Biotech · Feb 7, 2025
- Second Heart Assist, Inc.$17M · Biotech · Feb 7, 2025
- Rebel Medicine Inc$9M · Other health care · Feb 21, 2025
- 3Helix, Inc.$8M · Biotech · Sep 21, 2026
- Paterna BioSciences HoldCo Inc.$6M · Biotech · Aug 12, 2026
- SeeLife Impact 6 LLC$5M · Biotech · Jan 20, 2026
- SeeLife Impact 4 LLC$5M · Biotech · Jan 20, 2026
- SeeLife Impact 3 LLC$5M · Biotech · Jan 20, 2026
State Attorney General Health-Care Cases
Antitrust cases Utah joined, newest first; see every case- Connecticut, et al. v. Sandoz, et al., Case No. 20-cv-3539 (E.D. Pa. June 10, 2020), MDL 2724 (E.D. Pa.)2020 · Pending
- Connecticut et al. v. Teva Pharmaceuticals USA, Inc. et al., No. 2:19-cv-02407, (E.D. Pa. filed in MDL 05/30/2019)2019 · Pending
- Alabama et al. v. Endo International, No. 3:19-cv-04157 (N.D. Cal. July 19, 2019)2019 · Settled
- State of Wisconsin et al. v. Indivior, No. 16-5073 (E.D. Pa. Sept. 22,2016)2016 · Pending
- New York et al. v. Cephalon, No. 2:16-cv-04234 (E.D. Pa. Aug. 4, 2016)2016 · Settled
- Maryland v. SmithKline Beecham Corp., No. 2:06-cv-01298-JP (E.D.Pa Mar. 27, 2006)2006 · Settled
- State of Colorado et al v. Warner Chilcott, 1:05-cv-02182 (D.D.C.2005)2005 · Settled
- Maryland et al. v. Perrigo Company, No. 1:04CV01398 (D.D.C. Aug. 17, 2004)2004 · Settled
- Texas et al. v. Organon (Remeron), No. 04-5126 (D.N.J. 2004)2004 · Settled
- In re Cardizem CD Antitrust Litigation 99-MD-1278 (E.D. Mich. Jan. 29, 2003), 332 F.3d 896 (6th Cir. 2003)2003 · Settled
Other States
Alabama · Alaska · Arizona · Arkansas · California · Colorado · Connecticut · Delaware · District of Columbia · Florida · Georgia · Hawaii · Idaho · Illinois · Indiana · Iowa · Kansas · Kentucky · Louisiana · Maine · Maryland · Massachusetts · Michigan · Minnesota · Mississippi · Missouri · Montana · Nebraska · Nevada · New Hampshire · New Jersey · New Mexico · New York · North Carolina · North Dakota · Ohio · Oklahoma · Oregon · Pennsylvania · Puerto Rico · Rhode Island · South Carolina · South Dakota · Tennessee · Texas · Vermont · Virginia · Washington · West Virginia · Wisconsin · Wyoming
Part D is by the prescriber's state, Medicaid by the paying state program, and Form D by the issuer's stated address. Amounts are before manufacturer rebates. Refreshed weekly. CMS Medicare Part D Prescribers by Geography; CMS State Drug Utilization Data; SEC Form D; NAAG